175 related articles for article (PubMed ID: 29735551)
61. Case study interpretation-New Orleans: case 4. Richter syndrome characterized by diffuse large B cell lymphoma in the context of prior chronic lymphocytic leukemia/small lymphocytic lymphoma.
Linden MA
Cytometry B Clin Cytom; 2013; 84(5):350-3. PubMed ID: 23283841
[No Abstract] [Full Text] [Related]
62. Constitutive activation of NF-κB signaling by NOTCH1 mutations in chronic lymphocytic leukemia.
Xu ZS; Zhang JS; Zhang JY; Wu SQ; Xiong DL; Chen HJ; Chen ZZ; Zhan R
Oncol Rep; 2015 Apr; 33(4):1609-14. PubMed ID: 25633905
[TBL] [Abstract][Full Text] [Related]
63. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
[TBL] [Abstract][Full Text] [Related]
64. Richter syndrome with two B cell clones possessing different surface immunoglobulins and immunoglobulin gene rearrangements.
Tohda S; Morio T; Suzuki T; Nagata K; Kamiyama T; Imai Y; Nara N; Aoki N
Am J Hematol; 1990 Sep; 35(1):32-6. PubMed ID: 2202205
[TBL] [Abstract][Full Text] [Related]
65. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
[TBL] [Abstract][Full Text] [Related]
66. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
[TBL] [Abstract][Full Text] [Related]
67. A rare case of empyema. Answer: Transformation of CLL into diffuse large B-cell lymphoma, also known as Richter syndrome.
Yager NM; Ghate K; Swan RL; Farrokh A; Barba K; Beegle SH
Chest; 2013 Jul; 144(1):350-353. PubMed ID: 23880686
[No Abstract] [Full Text] [Related]
68. Richter transformation of chronic lymphocytic leukemia into composite diffuse large B-cell and Hodgkin lymphoma.
Michelis FV; Kourti G; Skertsou M; Karmiris T; Rontogianni DP; Harhalakis N
Leuk Lymphoma; 2012 Nov; 53(11):2302-3. PubMed ID: 22432520
[No Abstract] [Full Text] [Related]
69. New developments in Richter syndrome.
Jain N
Clin Adv Hematol Oncol; 2015 Apr; 13(4):220-2. PubMed ID: 26352579
[No Abstract] [Full Text] [Related]
70. Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Agbay RL; Jain N; Loghavi S; Medeiros LJ; Khoury JD
Am J Hematol; 2016 Oct; 91(10):1036-43. PubMed ID: 27414262
[TBL] [Abstract][Full Text] [Related]
71. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.
Matolcsy A; Chadburn A; Knowles DM
Am J Pathol; 1995 Jul; 147(1):207-16. PubMed ID: 7541611
[TBL] [Abstract][Full Text] [Related]
72. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
73. Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies.
Seelig DM; Ito D; Forster CL; Yoon UA; Breen M; Burns LJ; Bachanova V; Lindblad-Toh K; O'Brien TD; Schmechel SC; Rizzardi AE; Modiano JF; Linden MA
Leuk Lymphoma; 2017 Jul; 58(7):1702-1710. PubMed ID: 27931134
[TBL] [Abstract][Full Text] [Related]
74. Richter Transformation in Chronic Lymphocytic Leukemia: Update in the Era of Novel Agents.
Tadmor T; Levy I
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680290
[TBL] [Abstract][Full Text] [Related]
75. Aggressive lymphomas.
Lenz G; Staudt LM
N Engl J Med; 2010 Apr; 362(15):1417-29. PubMed ID: 20393178
[TBL] [Abstract][Full Text] [Related]
76. CT manifestations of Richter syndrome.
Cohen LM; Hill MC; Siegel RS; Lande IM
J Comput Assist Tomogr; 1987; 11(6):1007-8. PubMed ID: 3316323
[TBL] [Abstract][Full Text] [Related]
77. Epcoritamab, a promising therapy for Richter syndrome?
Kater A
Clin Adv Hematol Oncol; 2024 Mar; 22(2):90-91. PubMed ID: 38446476
[No Abstract] [Full Text] [Related]
78. Tracking CLL's Transformation to RS.
Cancer Discov; 2023 Mar; 13(3):523-524. PubMed ID: 36625568
[TBL] [Abstract][Full Text] [Related]
79. Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization.
Moulin C; Guillemin F; Remen T; Bouclet F; Hergalant S; Quinquenel A; Dartigeas C; Tausch E; Lazarian G; Blanchet O; Lomazzi S; Chapiro E; Schneider C; Nguyen-Khac F; Davi F; Hunault M; Tomowiak C; Roos-Weil D; Siebert R; Thieblemont C; Cymbalista F; Laribi K; Béné MC; Stilgenbauer S; Guièze R; Feugier P; Broséus J
Am J Hematol; 2021 Sep; 96(9):E311-E314. PubMed ID: 34000073
[No Abstract] [Full Text] [Related]
80. Prognostication in Richter syndrome: context is everything.
Eyre TA
Br J Haematol; 2020 Sep; 190(6):811-812. PubMed ID: 32420622
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
